Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
The PASS-PD study aims to find people in the general population who may be at a higher risk of developing Parkinson's disease. By following these individuals for five years, researchers hope to better understand the early signs, including non-motor symptoms like sleep problems or changes in smell, and how the condition progresses. The study also looks at how to talk ethically and responsibly about these early risks with individuals. It doesn't involve any new treatments or interventions; instead, it focuses on observation, collecting information, and using biological markers to improve our ability to predict Parkinson's and identify different types of the disease. The goal is to make future diagnoses and support better.
A colpo d'occhio
Di cosa tratta questo studio?
The Parkinson's Disease (PD) study, called PASS-PD, is designed to help us understand more about who might get Parkinson's disease in the future and why. Researchers are interested in finding people who show signs that could mean they have a higher chance of developing the condition, even if they don't have it right now. They want to follow these people over five years to see how things develop.
This study is important because it will help doctors and researchers learn more about the very early stages of Parkinson's disease. This includes looking at things beyond the more obvious movement problems, such as changes in sleep, mood, or sense of smell. By understanding these 'non-motor' symptoms better, and combining this with information from biological tests, we might be able to predict Parkinson's disease earlier and understand different forms it can take.
Another key part of this study is making sure that any information about someone's future risk of Parkinson's is shared in a careful and ethical way. It's all about gathering knowledge to help us better understand, diagnose, and eventually manage Parkinson's disease in the future.
Punti chiave
- A study searching for early signs of Parkinson's disease.
- No new treatments are involved, it's about observation and learning.
- Participants will be followed for five years.
- Aims to understand risk factors and different types of Parkinson's.
- Helps improve future diagnosis and support for others.
- Results will be shared carefully and ethically.
Chi può essere idoneo?
This study is looking for participants who are aged between 50 and 99 years old. It's open to everyone, regardless of gender.
You would not be able to take part if you have already been diagnosed with Parkinson's disease or if you have other serious brain or nerve conditions, like Multiple Sclerosis. Also, if you have other significant health problems, for example, certain bone or joint conditions that might make it hard to do movement tests, you wouldn't be eligible.
For a small group of participants who might be asked to have a special test called a lumbar puncture (spinal tap), certain medical conditions or medications that affect blood clotting would prevent you from taking part in that specific part of the study.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you between 50 and 99 years old?
- Have you been diagnosed with Parkinson's disease already? (If yes, you can't join.)
- Do you have other serious brain or nerve conditions? (If yes, you can't join.)
- Do you have other major illnesses that might affect movement tests, like severe arthritis or bone problems? (If yes, you might not be able to join.)
- For the optional spinal fluid test: Do you have issues with bleeding or take blood thinners? (If yes, you can't have this specific test.)
Cosa comporta la partecipazione?
If you take part in the study, you won't be receiving any new treatments or medicines. Instead, it's about observation and gathering information. Researchers will follow up with you over a period of five years. This will involve regular visits where they will carry out various assessments, such as looking at your signs and symptoms, and possibly collecting samples for biological tests. The exact number of visits and tests will be explained in detail if you are considered for the study. Your commitment would be to attend these appointments as scheduled over the five-year period.
Rischi e benefici potenziali
Luoghi (1)
- Department for Neurology, University of KielCodice postale verificatoKiel, Germania· Reclutamento
Domande comuni
Che cos’è la malattia di Parkinson?
Parkinson's disease is a condition that affects the brain and can cause problems with movement, like shaking, stiffness, and difficulty with balance. It can also cause other symptoms, like sleep problems or changes in mood.
Will I get any medicine or treatment in this study?
No, this study is not about trying out new medicines or treatments. It's an observational study, which means researchers will be watching and collecting information to learn more about Parkinson's disease.
What does a 'biological marker' mean?
Biological markers are things found in your blood, spinal fluid, or other body parts that can give doctors clues about your health or a particular condition. In this study, they're looking for markers that might help predict Parkinson's disease.
Per quanto tempo sarò coinvolto nello studio?
If you take part, researchers will follow up with you for a period of five years, attending regular appointments during that time.
What does 'ethical handling of early risk disclosure' refer to?
This means that if the study finds you might be at a higher risk of developing Parkinson's in the future, the researchers will have a very careful and sensitive way of sharing this information with you, ensuring you have support and understand what it means.
Come saperne di più
Eva Schaeffer, Dr.
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.